2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors
Top Cited Papers
- 1 April 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 121 (4), 829-846
- https://doi.org/10.1097/aog.0b013e3182883a34
Abstract
A group of 47 experts representing 23 professional societies, national and international health organizations, and federal agencies met in Bethesda, MD, September 14-15, 2012, to revise the 2006 American Society for Colposcopy and Cervical Pathology Consensus Guidelines. The group's goal was to provide revised evidence-based consensus guidelines for managing women with abnormal cervical cancer screening tests, cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) following adoption of cervical cancer screening guidelines incorporating longer screening intervals and co-testing. In addition to literature review, data from almost 1.4 million women in the Kaiser Permanente Northern California Medical Care Plan provided evidence on risk after abnormal tests. Where data were available, guidelines prescribed similar management for women with similar risks for CIN 3, AIS, and cancer. Most prior guidelines were reaffirmed. Examples of updates include: Human papillomavirus-negative atypical squamous cells of undetermined significance results are followed with co-testing at 3 years before return to routine screening and are not sufficient for exiting women from screening at age 65 years; women aged 21-24 years need less invasive management, especially for minor abnormalities; postcolposcopy management strategies incorporate co-testing; endocervical sampling reported as CIN 1 should be managed as CIN 1; unsatisfactory cytology should be repeated in most circumstances, even when HPV results from co-testing are known, while most cases of negative cytology with absent or insufficient endocervical cells or transformation zone component can be managed without intensive follow-up. (Obstet Gynecol 2013;121:829-46) DOI: http://10.1097/AOG.0b013e3182883a34This publication has 89 references indexed in Scilit:
- Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2012
- Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practiceThe Lancet Oncology, 2011
- Age distribution of HPV genotypes in cervical intraepithelial neoplasiaGynecologic Oncology, 2011
- Management of Papanicolaou test results that lack endocervical cellsCMAJ : Canadian Medical Association Journal, 2011
- Rate of and Risks for Regression of Cervical Intraepithelial Neoplasia 2 in Adolescents and Young WomenObstetrics & Gynecology, 2010
- Comparison of Measurements of Human Papillomavirus Persistence for Postcolposcopic Surveillance for Cervical Precancerous LesionsCancer Epidemiology, Biomarkers & Prevention, 2010
- Lessons From PracticeJournal of Lower Genital Tract Disease, 2010
- Chapter 9: Clinical applications of HPV testing: A summary of meta-analysesVaccine, 2006
- Treatment for Cervical Intraepithelial Neoplasia and Risk of Preterm DeliveryPublished by American Medical Association (AMA) ,2004
- Natural History of Cervical Intraepithelial NeoplasiaInternational Journal of Gynecological Pathology, 1993